A new era of cushing disease therapeutics

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cushing syndrome (CS) is a severe clinical condition caused by prolonged and inappropriate exposure to cortisol. Excluding exogenous cortisol excess, adrenocorticotropic hormone (ACTH) secretion from a pituitary adenoma, also called Cushing disease (CD), represents by far the most common CS etiology. Since Harvey Cushing first reported the classical clinical syndrome over 100 years ago, much clinical progress has been made, however disease management remains a challenge both in terms of diagnosis and treatment. Treatment is often complex and may require surgery, medical management and radiotherapy. Here we focus on the key findings of recent clinical trials with new therapeutic agents (1-3) and discuss how these new treatments fit in the armamentarium for patients with CD.

Original languageEnglish (US)
Pages (from-to)89-96
Number of pages8
JournalActa Endocrinologica
Volume9
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Pituitary ACTH Hypersecretion
Cushing Syndrome
Hydrocortisone
Pituitary Neoplasms
Therapeutics
Disease Management
Adrenocorticotropic Hormone
Radiotherapy
Clinical Trials

Keywords

  • Adrenocorticotropic hormone
  • Cushing disease
  • Cushing syndrome
  • Medical management
  • Pituitary adenoma

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

A new era of cushing disease therapeutics. / Fleseriu, Maria; McCartney, Shirley.

In: Acta Endocrinologica, Vol. 9, No. 1, 01.2013, p. 89-96.

Research output: Contribution to journalArticle

@article{07cd8b8ca7924de2a337ba7142c38931,
title = "A new era of cushing disease therapeutics",
abstract = "Cushing syndrome (CS) is a severe clinical condition caused by prolonged and inappropriate exposure to cortisol. Excluding exogenous cortisol excess, adrenocorticotropic hormone (ACTH) secretion from a pituitary adenoma, also called Cushing disease (CD), represents by far the most common CS etiology. Since Harvey Cushing first reported the classical clinical syndrome over 100 years ago, much clinical progress has been made, however disease management remains a challenge both in terms of diagnosis and treatment. Treatment is often complex and may require surgery, medical management and radiotherapy. Here we focus on the key findings of recent clinical trials with new therapeutic agents (1-3) and discuss how these new treatments fit in the armamentarium for patients with CD.",
keywords = "Adrenocorticotropic hormone, Cushing disease, Cushing syndrome, Medical management, Pituitary adenoma",
author = "Maria Fleseriu and Shirley McCartney",
year = "2013",
month = "1",
doi = "10.4183/aeb.2013.89",
language = "English (US)",
volume = "9",
pages = "89--96",
journal = "Acta Endocrinology",
issn = "0001-5598",
publisher = "Munksgaard International Publishers",
number = "1",

}

TY - JOUR

T1 - A new era of cushing disease therapeutics

AU - Fleseriu, Maria

AU - McCartney, Shirley

PY - 2013/1

Y1 - 2013/1

N2 - Cushing syndrome (CS) is a severe clinical condition caused by prolonged and inappropriate exposure to cortisol. Excluding exogenous cortisol excess, adrenocorticotropic hormone (ACTH) secretion from a pituitary adenoma, also called Cushing disease (CD), represents by far the most common CS etiology. Since Harvey Cushing first reported the classical clinical syndrome over 100 years ago, much clinical progress has been made, however disease management remains a challenge both in terms of diagnosis and treatment. Treatment is often complex and may require surgery, medical management and radiotherapy. Here we focus on the key findings of recent clinical trials with new therapeutic agents (1-3) and discuss how these new treatments fit in the armamentarium for patients with CD.

AB - Cushing syndrome (CS) is a severe clinical condition caused by prolonged and inappropriate exposure to cortisol. Excluding exogenous cortisol excess, adrenocorticotropic hormone (ACTH) secretion from a pituitary adenoma, also called Cushing disease (CD), represents by far the most common CS etiology. Since Harvey Cushing first reported the classical clinical syndrome over 100 years ago, much clinical progress has been made, however disease management remains a challenge both in terms of diagnosis and treatment. Treatment is often complex and may require surgery, medical management and radiotherapy. Here we focus on the key findings of recent clinical trials with new therapeutic agents (1-3) and discuss how these new treatments fit in the armamentarium for patients with CD.

KW - Adrenocorticotropic hormone

KW - Cushing disease

KW - Cushing syndrome

KW - Medical management

KW - Pituitary adenoma

UR - http://www.scopus.com/inward/record.url?scp=84876081642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876081642&partnerID=8YFLogxK

U2 - 10.4183/aeb.2013.89

DO - 10.4183/aeb.2013.89

M3 - Article

AN - SCOPUS:84876081642

VL - 9

SP - 89

EP - 96

JO - Acta Endocrinology

JF - Acta Endocrinology

SN - 0001-5598

IS - 1

ER -